CHELMSFORD, Mass., May 29 /PRNewswire/ -- Magellan Biosciences, an emerging leader in clinical-diagnostics markets worldwide, will feature automated systems and assays designed to streamline microbiology testing and improve health outcomes for patients at the 108th meeting of the American Society for Microbiology (ASM). Magellan subsidiaries, TREK Diagnostic Systems and Dynex Technologies, will share booth 743 at the exhibition, which runs Monday through Wednesday, June 2-4, 2008, at the Boston Convention and Exhibition Center. TREK scientists are also presenting a number of technical posters during the conference.
TREK will highlight its new Sensititre(R) Gram positive all-in-one dry, microbroth dilution plates -- the only MIC plates cleared by the FDA for D-Test and Cefoxitin screening, Daptomycin and Vancomycin confirmation, as well as numerous other antimicrobics. The D-Test detects inducible resistance to Clindamycin -- a drug commonly used for treating community-acquired Methicillin Resistant Staphylococcus aureus (MRSA), particularly in pediatric populations. The Cefoxitin Screen procedure is the most-sensitive test available to detect low-level Methicillin and Oxacillin (MRSA) resistance. In addition, TREK will demonstrate its new Vizion(TM) System*, which adds easy-to-read digital imaging capability to the company's Sensititre(R) Automated Susceptibility and Identification Testing System. Vizion is the only system that enables users to save and store digital images of susceptibility results for consultations, quality control, and training. The Sensititre/Vizion system enables easy and accurate antimicrobial-resistance detection of all organism groups, including fastidious isolates, such as Haemophilus, Streptococcus, Mycobacteria, and yeast. The award-winning VersaTREK(R) Automated Microbial Detection System will also be on view.
Dynex will feature its much-heralded DS2(R) automated two-plate ELISA processing system, which provides full walk-away capability to busy microbiology labs. Reliable, cost-effective, and easy to use and maintain, the DS2 packs full automation power in the smallest footprint available. The system quickly and easily processes two 96-well microplates and up to 12 different assays simultaneously and features the most user-friendly control system available, chain of custody, and instrument diagnostics.
"MRSA is a growing concern in healthcare," said Magellan President and CEO, Robert J. Rosenthal, Ph.D. "Managers of microbiology labs are looking for integrated systems that streamline testing, take the guesswork out of identifying often difficult-to-read results, reduce errors from manual methods, and provide faster turnaround times at a lower cost per result. TREK's Sensititre System delivers, testing for the widest range of resistant organisms in one platform." Regarding the Dynex DS2, Dr. Rosenthal remarked, "Doctors rely on fast, accurate, and reliable results from diagnostic tests to make good treatment decisions. Today, there's a critical shortage of qualified laboratory personnel, and most hospital-based microbiology labs have neither the space nor throughput requirements to justify large-scale automated systems. That's why Dynex designed the easy-to-use DS2 system, which delivers sample-in/results-out automation of virtually any ELISA microplate assay."
About Magellan Biosciences (http://www.magellanbio.com)
Magellan serves the worldwide clinical-diagnostics market with rapid point-of-care analyzers and automated systems for hospital-based labs and near-patient testing. Scientists use the company's discovery systems and sensors for cutting-edge research to develop a new understanding of health and illness -- from disease pathology to biomarker identification. Magellan designs all its systems, sensors, and consumables to deliver better, more-reliable results. And better results help drive improved health outcomes: earlier, more-accurate diagnoses; breakthroughs that can lead to novel treatments, new cures -- innovations to enhance life. A privately held company, Magellan serves customers through wholly owned subsidiaries: ESA Biosciences, Dynex Technologies, and TREK Diagnostic Systems.
About TREK Diagnostic Systems (http://www.trekds.com)
A Magellan Biosciences company and leader in automated systems and consumables for microbiology-based diagnostic testing, TREK serves the clinical, pharmaceutical, and veterinary markets. TREK's VersaTREK(R) Automated Microbial Detection System and Sensititre(R) Automated Susceptibility and Identification Testing System, are designed to provide cost-effective improvements in workflow efficiencies, ergonomics, and results performance.
About Dynex Technologies (http://www.dynextechnologies.com)
A Magellan Biosciences company, Dynex Technologies is the innovator in automated and semi-automated technologies for microplate analysis. From walk-away ELISA processing stations like its powerful, two-plate DS2 for low-throughput labs to the renowned four-plate DSX -- Dynex designs each of its products to meet the rigorous demands of scientists in clinical, biomedical, and pharmaceutical-development applications.
*Pending FDA clearance. Not yet for sale in the US.
|SOURCE Magellan Biosciences|
Copyright©2008 PR Newswire.
All rights reserved